Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1489101 | 0.82 | ALDH1A1 (0.44) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| Acetic Acid SCHEMBL28451523 | 0.79 | ALDH1A1 (0.34) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL169909 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL3469849 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1257020 | 0.78 | TSHR (0.40) | ALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL612528 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL28514951 | 0.76 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL10784897 | 0.76 | KDM4E (0.33) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3453844 | 0.75 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2A | |
| SCHEMBL986380 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | claimed |
| EP-2473475-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | AllTranz Inc. (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | claimed |
| WO-2011026144-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | WO | claimed |
| EP-2176208-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-04-21 | — | — | EP | claimed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | claimed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-11873272-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | Niche Biopharmaceuticals LLC (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4214191-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | Niche Biopharmaceuticals LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116323556-A | Antimicrobial and antiviral sulfur-containing monoglyceride derivatives | 尼奇生物制药有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230174473-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | Niche Biopharmaceuticals LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-11572342-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | Niche Biopharmaceuticals LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11365176-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | Niche Biopharmaceuticals LLC (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2011026144-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2176208-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-0842142-A1 | PROCESS FOR PRODUCING $g(a)-(N,N DIALKYL)-AMINO CARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997005096-A1 | PROCESS FOR PRODUCING α-(N,N DIALKYL)-AMINO CARBOXYLIC ACID AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 1490/4885LMNA 1353/4885MEN1 3729/4885 |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | ALDH1A1 3684/4885LMNA 3547/4885MEN1 1518/4885 |
| US-11572342-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | MAVS, SARS1, MGLL | ALDH1A1 3686/4885LMNA 4761/4885MEN1 3893/4885 |
| US-11873272-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | MAVS, SARS1, MGLL | ALDH1A1 3686/4885LMNA 4761/4885MEN1 3893/4885 |
| US-20230174473-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | MAVS, SARS1, MGLL | ALDH1A1 3686/4885LMNA 4761/4885MEN1 3893/4885 |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | ALDH1A1 3684/4885LMNA 3547/4885MEN1 1518/4885 |
| US-11365176-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | MAVS, SARS1, MGLL | ALDH1A1 3686/4885LMNA 4761/4885MEN1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.